BioGaia AB (publ) (BIOGY) Q3 2025 Earnings Call Transcript

BioGaia AB reported robust Q3 2025 sales of SEK 327 million, representing a 14% increase excluding currency effects, primarily driven by strong growth in the Americas (+10%) and Asia Pacific (+17%) due to increased media investments in key direct markets. The company achieved an EBIT of SEK 86 million, resulting in a 26% EBIT margin, a significant improvement from 14% in the prior year which was affected by an impairment loss. Year-to-date, BioGaia's EBIT margin stands at 27%, reflecting enhanced profitability alongside its strategic focus on core health segments.

Analysis

BioGaia AB (OTCPK:BIOGY) reported robust Q3 2025 sales of SEK 327 million, marking a 14% year-over-year increase when excluding currency effects, significantly outperforming the 7% reported growth. This strong performance was primarily driven by substantial growth in Asia Pacific (+17%) and Americas (+10%), attributed to increased media investments in key direct markets like the U.S., Canada, U.K., and Australia. These investments successfully attracted new consumers and enhanced brand awareness, underpinning the core strategy of growing existing segments.

Profitability saw a notable improvement, with Q3 EBIT reaching SEK 86 million, translating to a 26% EBIT margin. This represents a significant expansion from the 14% EBIT margin recorded in the prior year, which was negatively impacted by a SEK 51 million MetaboGen impairment loss. The year-to-date EBIT margin stands even higher at 27%, indicating sustained operational efficiency and a strong recovery in profitability post-impairment.

While growth was strong in key regions, EMEA experienced a 4% decrease in sales, primarily due to Eastern Europe, highlighting regional disparities in performance. The company's strategic pillars, focusing on "Grow the Core" in gut, colic, oral, and immune health, appear to be effectively leveraging increased marketing spend to drive top-line growth and market penetration in prioritized areas, contributing to the overall optimistic sentiment.

Key Decisions for Investors

• Investors should closely monitor BioGaia's continued sales momentum, particularly the effectiveness of increased media investments in driving growth in the Americas and Asia Pacific.
• Evaluate the sustainability of the improved 26% EBIT margin, considering the prior year's impairment impact and the year-to-date 27% margin as a new baseline for profitability.
• Assess the company's strategy to address regional sales declines, specifically in EMEA, and its ability to consistently execute on its "Grow the Core" pillars for sustained market share gains.